Top 18 tagrisso.com competitors & alternatives
[Treatment for Certain Types of EGFR+ NSCLC | TAGRISSO® (osimertinib) Learn about TAGRISSO® (osimertinib), a targeted treatment option for people with certain types of EGFR+ non-small cell lung cancer (NSCLC). Talk to your doctor to see if TAGRISSO is right for you.]
tagrisso.com competitors and alternatives
Top 18 tagrisso.com competitors and alternatives are ranked by similar search terms, traffic and worth.
tagrisso.com's top 5 competitors are: astrazeneca-us.com with 4,680 daily traffic and 138,900 estimated worth, lcfamerica.org with 0 daily traffic and 79,600 estimated worth, imfinzi.com with 100 daily traffic and 49,000 estimated worth, astrazeneca.ca with 1,500 daily traffic and 46,500 estimated worth, tarceva.com with 0 daily traffic and 11,400 estimated worth.
astrazeneca-us.com
AstraZeneca US - Innovative Biopharmaceuticals and Healthcare Solutions
Discover AstraZeneca's commitment to developing innovative medicines and healthcare solutions in the US. Learn about our therapies, research, and patient-first approach.
Daily Traffic: 4,680
Website Worth: $ 138,900
lcfamerica.org
Lung Cancer Foundation of America: Research and Awareness
Lung Cancer Foundation of America mission is dedicated to improving survivorship by funding transformative lung cancer research. Learn how you can help.
Daily Traffic: 0
Website Worth: $ 79,600
imfinzi.com
Immunotherapy for BTC, uHCC, NSCLC & ES-SCLC - IMFINZI® (durvalumab)
IMFINZI® (durvalumab) is an immunotherapy approved to treat patients with unresectable hepatocellular carcinoma, bile duct cancer, gallbladder cancer, unresectable Stage 3 NSCLC, Stage 4 NSCLC, and extensive-stage SCLC.
Daily Traffic: 100
Website Worth: $ 49,000
astrazeneca.ca
AstraZeneca Canada | Innovative Healthcare Solutions
Discover AstraZeneca's commitment to advancing healthcare in Canada. Explore our innovative medicines and efforts to improve patient outcomes across various therapeutic areas.
Daily Traffic: 1,500
Website Worth: $ 46,500
tarceva.com
Tarceva® (erlotinib) for Advanced Non-Small Cell Lung Cancer (NSCLC) Treatment
Information about Tarceva® (erlotinib) tablets as maintenance treatment for advanced stage non-small cell lung cancer (NSCLC).
Tarceva is prescribed for patients with advanced-stage non-small cell lung cancer (NSCLC) whose cancer has not spread or grown after initial treatment with certain types of chemotherapy. (Maintenance treatment)
Tarceva is prescribed for patients with advanced-stage non-small cell lung cancer (NSCLC) whose cancer has spread or grown after receiving at least 1 chemotherapy regimen. (2nd-/3rd-line treatment)
Tarceva is not meant to be used at the same time as certain types of chemotherapy for NSCLC.
Important Safety Information
Possible effects on the lungs
There have been reports of serious adverse events involving the lungs in a small number of patients taking Tarceva. These events have included death in some patients. The medical name for these types of events is interstitial (in-tur-STISH-ul) lung disease-like events (or ILD-like events).
Possible effects on the kidneys and liver
Liver and/or kidney problems (including deaths) have been reported in some patients taking Tarceva. Let your healthcare provider (HCP) know if you have a history of liver or kidney disease.
Possible effects on the stomach and intestines
Some patients taking Tarceva have developed a hole in the lining of their stomach or intestines (including deaths). It may happen more in patients who are taking certain other medicines or who have had certain stomach or intestinal diseases.
Possible effects on the skin
Some patients taking Tarceva have developed serious skin conditions. Some patients have died from these conditions.
Possible effects on the eye
Some patients taking Tarceva have developed eye irritation and damage to the cornea. The cornea is the clear part of the eyeball that covers the colored part of the eye and the pupil. Other eye problems such as abnormal eyelash growth, dry eyes, or changes in eyesight have also been reported. Patients should
Daily Traffic: 0
Website Worth: $ 11,400
indianpharmanetwork.co.in
Pharmaceutical Products - Legitimate Healthcare Consultant And Facilitator In Delhi
Indian Pharma Network www.indianpharmanetwork.co.in is a comprehensive platform that connects pharmaceutical professionals, suppliers, manufacturers, and distributors across India.
Daily Traffic: 480
Website Worth: $ 4,600
tagrissohcp.com
Treatment for Resectable and Metastatic EGFRm NSCLC - TAGRISSO® (osimertinib)
Learn about TAGRISSO® (osimertinib), a targeted therapy for resectable EGFRm non-small cell lung cancer (NSCLC) and the first-line treatment of metastatic EGFRm NSCLC.
Daily Traffic: 0
Website Worth: $ 0
tecentriq.com
cancer immunotherapy treatment for nsclc, es-sclc, hcc, & advanced melanoma | tecentriq® (atezolizumab)
learn about tecentriq® (atezolizumab), a cancer immunotherapy treatment for non-small cell lung cancer after surgery and chemo, metastatic non-small cell lung cancer (nsclc), extensive-stage small cell lung cancer (es-sclc), liver cancer (hcc), & advanced melanoma | tecentriq® (atezolizumab)
Daily Traffic: 0
Website Worth: $ 0
myaccess360.com
My Access 360 | Helping Patients Access the Care They Need
The Access 360 program provides personal support to connect patients to affordability programs and streamline access and reimbursement for select AstraZeneca medicines.
Daily Traffic: 0
Website Worth: $ 0
egfrcancer.org
EGFR Lung Cancer Resisters Group
Patient-driven advocacy group united with the goal of finding a cure for EGFR lung cancer. Join EGFR Lung Cancer Resisters advocacy group today!
Daily Traffic: 0
Website Worth: $ 0
tagrisso-global.com
TAGRISSO® (osimertinib) | Official Global Site
Discover the new first-line TAGRISSO efficacy (PFS) data in NSCLC and access information about safety, MOA, dosing, AURA3 and other resources
Daily Traffic: 0
Website Worth: $ 0
Share on Social Media
Similar sites like tagrisso.com